MX2023014197A - Compuestos de azetidinilo que comprenden un grupo de acido carboxilico para el tratamiento de enfermedades neurodegenerativas. - Google Patents
Compuestos de azetidinilo que comprenden un grupo de acido carboxilico para el tratamiento de enfermedades neurodegenerativas.Info
- Publication number
- MX2023014197A MX2023014197A MX2023014197A MX2023014197A MX2023014197A MX 2023014197 A MX2023014197 A MX 2023014197A MX 2023014197 A MX2023014197 A MX 2023014197A MX 2023014197 A MX2023014197 A MX 2023014197A MX 2023014197 A MX2023014197 A MX 2023014197A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- group
- carboxylic acid
- neurodegenerative diseases
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163211313P | 2021-06-16 | 2021-06-16 | |
| PCT/US2022/033523 WO2022266162A1 (en) | 2021-06-16 | 2022-06-15 | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014197A true MX2023014197A (es) | 2024-01-18 |
Family
ID=82595041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014197A MX2023014197A (es) | 2021-06-16 | 2022-06-15 | Compuestos de azetidinilo que comprenden un grupo de acido carboxilico para el tratamiento de enfermedades neurodegenerativas. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11919879B2 (enExample) |
| EP (1) | EP4355729A1 (enExample) |
| JP (1) | JP2024522718A (enExample) |
| KR (1) | KR20240021883A (enExample) |
| CN (1) | CN117500785A (enExample) |
| AR (1) | AR126159A1 (enExample) |
| AU (1) | AU2022291768A1 (enExample) |
| BR (1) | BR112023023420A2 (enExample) |
| CA (1) | CA3217423A1 (enExample) |
| IL (1) | IL308122A (enExample) |
| MX (1) | MX2023014197A (enExample) |
| TW (1) | TW202317534A (enExample) |
| WO (1) | WO2022266162A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022291768A1 (en) * | 2021-06-16 | 2023-11-30 | Celgene Corporation | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
| EP4633736A1 (en) * | 2022-12-16 | 2025-10-22 | Celgene Corporation | Heterocyclic compounds as modulators of s1p5 |
| CN121399098A (zh) | 2023-06-30 | 2026-01-23 | 赛诺菲 | 取代的环状化合物以及治疗苯丙酮尿症和其他氨基酸尿症的方法 |
| WO2026008750A1 (en) | 2024-07-05 | 2026-01-08 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO167087C (no) | 1985-10-25 | 1991-10-02 | Secr Defence Brit | Fremgangsmaate for fremstilling av en nitratester. |
| US5561227A (en) | 1991-07-23 | 1996-10-01 | Schering Corporation | Process for the stereospecific synthesis of azetidinones |
| LT3300B (en) | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
| HUP9901979A3 (en) | 1995-09-01 | 2000-03-28 | Upjohn Co | Phenyloxazolidinones having a c-c bond to 4-8 membered heterocyclic rings and pharmaceutical compositions containing the same |
| WO2000005214A2 (en) | 1998-07-24 | 2000-02-03 | Pfizer Inc. | Isoquinolines as urokinase inhibitors |
| ES2330731T3 (es) | 2001-08-30 | 2009-12-15 | Chemocentryx, Inc. | Compuestos biciclicos como inhibidores de la union de quimioquina a us28. |
| MXPA05000053A (es) | 2002-07-12 | 2005-04-08 | Aventis Pharma Gmbh | Benzoilureas heterociclicamente sustituidas, metodo para su produccion y su uso como medicamentos. |
| DE60335827D1 (de) | 2002-12-20 | 2011-03-03 | Merck Sharp & Dohme | 1-(amino)indane als edg-rezeptoragonisten |
| JP4660199B2 (ja) | 2002-12-23 | 2011-03-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換１−ピペリジン−４−イル−４−アゼチジン−３−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用 |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| AU2007227274A1 (en) * | 2006-03-21 | 2007-09-27 | Epix Delaware, Inc. | S1P receptor modulating compounds |
| WO2008053131A1 (en) | 2006-10-30 | 2008-05-08 | Chroma Therapeutics Ltd. | Hydroxamates as inhibitors of histone deacetylase |
| US20090137549A1 (en) | 2006-11-09 | 2009-05-28 | Paul John Edward | Novel compounds useful for the treatment of degenerative & inflamatory diseases |
| WO2010056788A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
| MX2011008452A (es) | 2009-02-10 | 2011-12-16 | Astrazeneca Ab | Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata. |
| WO2011036889A1 (ja) | 2009-09-25 | 2011-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
| GB201002563D0 (en) | 2010-02-15 | 2010-03-31 | Cambridge Entpr Ltd | Compounds |
| WO2011143365A1 (en) | 2010-05-13 | 2011-11-17 | Amgen Inc. | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
| MX2012013128A (es) | 2010-05-13 | 2013-03-20 | Amgen Inc | Compuestos heterociclicos de nitrogeno como inhibidores de la fosfodiesterasa 10. |
| WO2012082947A1 (en) | 2010-12-16 | 2012-06-21 | Irm Llc | Compounds and compositions as tgr5 agonists |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| MX336431B (es) | 2012-05-09 | 2016-01-18 | Zoetis Services Llc | Derivados de azetidina como agentes antiparasitarios. |
| TW201408652A (zh) | 2012-07-11 | 2014-03-01 | Hoffmann La Roche | 作爲ＲＯＲｃ調節劑之芳基磺內醯胺衍生物 |
| CA2891569A1 (en) | 2012-11-16 | 2014-05-22 | Bristol-Myers Squibb Company | Pyrrolidine gpr40 modulators |
| SG11201602935PA (en) | 2013-10-17 | 2016-05-30 | Abbvie Deutschland | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| KR20160100408A (ko) | 2014-01-06 | 2016-08-23 | 리젠 파마슈티컬스 소시에떼 아노님 | 신규한 글루타미나제 저해제 |
| FR3017867A1 (fr) * | 2014-02-21 | 2015-08-28 | Inventiva | Nouveaux composes de type phenylazetidine carboxylate ou carboxamide |
| EP3140296B1 (en) | 2014-05-07 | 2018-04-11 | Bristol-Myers Squibb Company | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes |
| EP3191453B1 (en) | 2014-09-09 | 2019-10-23 | Bristol-Myers Squibb Company | Phenyl-(aza)cycloalkyl carboxylic acid gpr120 modulators |
| US11219625B2 (en) | 2015-07-24 | 2022-01-11 | Yale University | Inhibitors of N-linked glycosylation and methods using same |
| JP6697074B2 (ja) | 2015-10-12 | 2020-05-20 | チョン クン ダン ファーマシューティカル コーポレーション | ヒストン脱アセチル化酵素６阻害剤としてのオキサジアゾールアミン誘導体化合物及びこれを含有する薬剤学的組成物 |
| EP3409658B9 (en) | 2016-01-29 | 2024-07-17 | ONO Pharmaceutical Co., Ltd. | Tetrahydronaphthalene derivative |
| DK3426243T3 (da) | 2016-03-09 | 2021-07-19 | Raze Therapeutics Inc | 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf |
| US20200321533A1 (en) | 2016-05-24 | 2020-10-08 | President And Fellows Of Harvard College | Compounds for organic light emitting diode materials |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| AR110988A1 (es) | 2017-02-21 | 2019-05-22 | Sanofi Sa | Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados |
| JP7365332B2 (ja) | 2017-08-07 | 2023-10-19 | ジョイント・ストック・カンパニー “バイオキャド” | Ｃｄｋ８／１９阻害薬としての新規ヘテロ環式化合物 |
| WO2019141803A1 (en) | 2018-01-19 | 2019-07-25 | Idorsia Pharmaceuticals Ltd | C5a receptor modulators |
| JP6828191B2 (ja) | 2018-08-16 | 2021-02-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血漿カリクレイン阻害剤としての複素芳香族カルボキサミド誘導体 |
| JP7571006B2 (ja) | 2018-08-17 | 2024-10-22 | ジェネンテック， インコーポレイテッド | 乳がんの処置のための診断的および治療的方法 |
| WO2020071550A1 (ja) | 2018-10-04 | 2020-04-09 | 京都薬品工業株式会社 | Ｃｄｋ８阻害剤およびその用途 |
| EP3873605B1 (en) | 2018-10-30 | 2024-10-23 | Gilead Sciences, Inc. | Compounds for inhibition of alpha4beta7 integrin |
| CN111484479B (zh) | 2019-01-25 | 2023-06-13 | 四川科伦博泰生物医药股份有限公司 | 氮杂环化合物、包含其的药物组合物及其制备方法和用途 |
| MX2022000083A (es) | 2019-07-03 | 2022-02-03 | Hoffmann La Roche | Inhibidores de monoacilglicerol lipasa (magl) heterociclicos. |
| MX2022001820A (es) | 2019-08-20 | 2022-03-17 | Ono Pharmaceutical Co | Sal y forma cristalina de un compuesto que tiene actividad agonista para el receptor 5 de esfingosina-1-fosfato [acido (2s,3r,4e)-2-amino-3-hidroxioctadeca-4-enil-1-fosforico (s1p5). |
| CN112887914A (zh) * | 2019-11-30 | 2021-06-01 | 深圳市海思半导体有限公司 | 终端间定位方法及装置 |
| CN111704613B (zh) | 2020-06-23 | 2021-07-06 | 中国人民解放军军事科学院军事医学研究院 | 咪唑类衍生物及其作为trpv4抑制剂的用途 |
| KR20230124992A (ko) | 2020-12-23 | 2023-08-28 | 셀진 코포레이션 | 신경변성 질환의 치료를 위한 카르복실산 함유 인다닐화합물 |
| AU2022291768A1 (en) * | 2021-06-16 | 2023-11-30 | Celgene Corporation | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
-
2022
- 2022-06-15 AU AU2022291768A patent/AU2022291768A1/en active Pending
- 2022-06-15 BR BR112023023420A patent/BR112023023420A2/pt not_active Application Discontinuation
- 2022-06-15 KR KR1020247001145A patent/KR20240021883A/ko active Pending
- 2022-06-15 US US17/840,876 patent/US11919879B2/en active Active
- 2022-06-15 EP EP22743647.4A patent/EP4355729A1/en active Pending
- 2022-06-15 JP JP2023577349A patent/JP2024522718A/ja active Pending
- 2022-06-15 CA CA3217423A patent/CA3217423A1/en active Pending
- 2022-06-15 WO PCT/US2022/033523 patent/WO2022266162A1/en not_active Ceased
- 2022-06-15 IL IL308122A patent/IL308122A/en unknown
- 2022-06-15 AR ARP220101582A patent/AR126159A1/es unknown
- 2022-06-15 TW TW111122266A patent/TW202317534A/zh unknown
- 2022-06-15 CN CN202280042673.6A patent/CN117500785A/zh active Pending
- 2022-06-15 MX MX2023014197A patent/MX2023014197A/es unknown
-
2024
- 2024-01-25 US US18/422,500 patent/US12552771B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12552771B2 (en) | 2026-02-17 |
| TW202317534A (zh) | 2023-05-01 |
| IL308122A (en) | 2023-12-01 |
| US11919879B2 (en) | 2024-03-05 |
| KR20240021883A (ko) | 2024-02-19 |
| US20230028747A1 (en) | 2023-01-26 |
| JP2024522718A (ja) | 2024-06-21 |
| WO2022266162A1 (en) | 2022-12-22 |
| EP4355729A1 (en) | 2024-04-24 |
| BR112023023420A2 (pt) | 2024-01-30 |
| US20240270714A1 (en) | 2024-08-15 |
| CA3217423A1 (en) | 2022-12-22 |
| CN117500785A (zh) | 2024-02-02 |
| AR126159A1 (es) | 2023-09-27 |
| AU2022291768A1 (en) | 2023-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023014197A (es) | Compuestos de azetidinilo que comprenden un grupo de acido carboxilico para el tratamiento de enfermedades neurodegenerativas. | |
| CO2020013155A2 (es) | Moduladores de nlrp3 | |
| ECSP24026455A (es) | Compuestos de pirrolotriazina como inhibidores de tam | |
| BR112022004802A2 (pt) | Moduladores de il-17a e usos dos mesmos | |
| CO2021006075A2 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| MY208545A (en) | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | |
| ECSP16072941A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| CL2020001742A1 (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades | |
| UY37272A (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
| MX2018003569A (es) | Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos. | |
| AR125457A2 (es) | Compuestos inhibidores dobles de magl y faah y composición farmacéutica | |
| CR20170187A (es) | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer | |
| BR112018067442A8 (pt) | Composto, composição farmacêutica, método de inibir a atividade da amina oxidase, método de tratar uma condição e uso de um composto | |
| MX2023000100A (es) | Compuestos diolicos de aminopirazina como inhibidores de fosfoinositida 3-cinasas-gamma. | |
| EA201890815A1 (ru) | Аминокислотные композиции с модифицированным высвобождением для перорального введения | |
| NZ713589A (en) | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level | |
| BR112015022577A2 (pt) | moduladores ship1 e métodos relacionados a esse | |
| MX2021011507A (es) | Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento. | |
| ECSP22044525A (es) | Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
| MX2021004134A (es) | Benzoxazol y compuestos relacionados útiles como moduladores de autofagia mediada por chaperonas. | |
| MX2019010174A (es) | Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple. | |
| UY37512A (es) | Compuestos pirazol 1,3-sustituido útiles para la reducción de los niveles de ácidos grasos de cadena muy larga | |
| MX375277B (es) | Métodos para tratar el síndrome de prader-willi | |
| CL2023001339A1 (es) | Un inhibidor de magl. | |
| MX2024007929A (es) | Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead. |